Abstract
The growing worldwide prevalence of type 2 Diabetes Mellitus (T2D) and dyslipidemia requires the identification of effective plant‐based management approaches, including the use of mulberry. However, the clinical evidence about the effects of mulberry on glucose and lipid profiles is inconsistent. This umbrella review studied evidence from five meta‐analyses (MAs) to comprehensively evaluate the impact of mulberry on glycemic and lipid profiles. Systematic searches were performed across major databases with methodological quality and certainty of evidence examined using AMSTAR‐2 and GRADE criteria, respectively. Low‐certainty evidence suggested that mulberry twig alkaloids reduced glycated hemoglobin (HbA1c) in adults with T2D compared with placebo (MD: −0.51%, 95% CI: −0.92 to −0.09). Moderate‐certainty evidence demonstrated that mulberry consumption significantly reduced fasting blood glucose (MD: −34.23 mg/dL, 95% CI: −55.13 to −13.33) and triglycerides (MD: −45.17 mg/dL, 95% CI: −70.86 to −19.49) in adults with T2D. In adults with medical conditions, mulberry also reduced total cholesterol (MD: −13.13 mg/dL; 95% CI: −19.06 to −7.20) and LDL‐C (MD: −8.84 mg/dL; 95% CI: −13.26 to −4.42), with low‐certainty evidence. By contrast, mulberry intake was not associated with changes in fasting plasma insulin and HDL‐C. All five MAs were rated as having critically low methodological quality according to AMSTAR‐2. Therefore, while mulberry may offer potential as a supportive supplement for cardiometabolic management, these findings should be interpreted with caution, are considered preliminary given the critically low methodological quality and the low‐to‐very‐low certainty of evidence for several statistically significant findings, and high‐quality clinical research is needed to strengthen the evidence base.

This publication has 24 references indexed in Scilit: